Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30007938HIVENSG00000101266.19protein_codingCSNK2A1NoNo1457P68400
TVIS30012830HIVENSG00000101266.19protein_codingCSNK2A1NoNo1457P68400
TVIS30007939HIVENSG00000101266.19protein_codingCSNK2A1NoNo1457P68400
TVIS30012831HIVENSG00000101266.19protein_codingCSNK2A1NoNo1457P68400
TVIS30088389HIVENSG00000101266.19protein_codingCSNK2A1NoNo1457P68400
TVIS30052769HIVENSG00000101266.19protein_codingCSNK2A1NoNo1457P68400
TVIS30052770HIVENSG00000101266.19protein_codingCSNK2A1NoNo1457P68400
TVIS30052771HIVENSG00000101266.19protein_codingCSNK2A1NoNo1457P68400
TVIS30052772HIVENSG00000101266.19protein_codingCSNK2A1NoNo1457P68400
TVIS30052773HIVENSG00000101266.19protein_codingCSNK2A1NoNo1457P68400
TCGA Plot Options
Drug Information
GeneCSNK2A1
DrugBank IDDB12010
Drug NameFostamatinib
Target IDBE0001209
UniProt IDP68400
Regulation Typeinhibitor
PubMed IDs26516587
CitationsRolf MG, Curwen JO, Veldman-Jones M, Eberlein C, Wang J, Harmer A, Hellawell CJ, Braddock M: In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib. Pharmacol Res Perspect. 2015 Oct;3(5):e00175. doi: 10.1002/prp2.175. Epub 2015 Sep 4.
GroupsApproved; Investigational
Direct ClassificationMethoxyanilines
SMILESCOC1=CC(NC2=NC=C(F)C(NC3=NC4=C(OC(C)(C)C(=O)N4COP(O)(O)=O)C=C3)=N2)=CC(OC)=C1OC
Pathways
PharmGKB
ChEMBLCHEMBL2103830